First Quadrant’s Puma Biotechnology PBYI Stock Holding History

First Quadrant’s Portfolio PBYI Stock Details PBYI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-23,500	Closed	-$228K	–	575
2021 Q1	$228K	Hold	23,500	–	–	0.02%	347
2020 Q4	$241K	Buy	+23,500	New	+$238K	0.02%	342
2020 Q2	–	Sell	-6,797	Closed	-$57K	–	807
2020 Q1	$57K	Buy	6,797 +3,364	+98%	+$32.7K	0.01%	520
2019 Q4	$30K	Buy	3,433 +2,021	+143%	+$16.7K	﹤0.01%	540
2019 Q3	$15K	Buy	+1,412	New	+$15.2K	﹤0.01%	573

Other funds holding PBYI

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FAM

Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

First Quadrant's PBYI Position: Q2 2021 in Review

First Quadrant sold out of Puma Biotechnology (PBYI) in Q2 2021, closing a stake of 23,500 shares — an estimated $228K sold.

First Quadrant first reported a position in PBYI in Q3 2019 and held it in 5 quarters. The position peaked at $241K in Q4 2020. 120 funds tracked by Wall St. Rank hold PBYI as of Q2 2021.

First Quadrant reported no remaining Puma Biotechnology position as of Q2 2021 after selling out during the quarter.
First Quadrant sold 23,500 Puma Biotechnology shares in Q2 2021, an estimated $228K.
First Quadrant first reported a position in Puma Biotechnology in Q3 2019 and held it in 5 quarters.
First Quadrant's Puma Biotechnology position peaked at $241K in Q4 2020.
120 funds tracked by Wall St. Rank held Puma Biotechnology as of Q2 2021.

Based on First Quadrant's 13F filing for Q2 2021, filed 23 Jul 2021.